Schema depicts the subjects screened for study, most common reasons for exclusion, numbers of eligible subjects enrolled and how they were randomized to study therapies, reasons for study discontinuation during the 16 wk of treatment interventions, and final numbers of evaluable subjects in the six allocation groups. NSAID, nonsteroidal antiinflammatory drug.